INS and type 2 diabetes mellitus: Provided that most of the antidiabetic agents are associated with weight gain [9,10] and the vast majority of patients with type 2 diabetes are overweight or obese [36], the introduction of SGLT2 inhibitors with an insulin independent mechanism could have a pivotal role in the management of type 2 diabetes.